Ascendis Pharma Director Buys 399,000 Shares in High‑Profile Warrant Exercise Amid Market Surge
Investor insight: Ascendis Pharma’s insider warrant exercise injects fresh capital and signals growth confidence, while diluting shares; watch how the funds accelerate its biotech pipeline and share price moves.
3 minutes to read


